-

Monsanto Wins Appeal Ruling in Erickson v. Monsanto

Court remands PCB case back to trial court for further proceedings

WHIPPANY, N.J.--(BUSINESS WIRE)--Today, a decision was issued by the Court of Appeals Division I in the State of Washington in Erickson v. Monsanto, ruling in Monsanto’s favor on multiple grounds.

This decision reverses the initial verdict of $185 million in its entirety and remands the case back to trial court for further proceedings.

The company stated:

“This is a very significant ruling in favor of Monsanto because the Court of Appeals identified multiple errors - that cut across most Sky Valley Education Center (SVEC) trials that have been completed - including the unreliability of Plaintiffs’ exposure evidence that was erroneously admitted in all SVEC cases tried to date. Specifically, the Court of Appeals held that the trial court improperly denied the Company’s statute of repose defense, erroneously admitted a major portion of plaintiffs’ key expert exposure opinions, and wrongfully allowed punitive damages on plaintiffs’ post-sale failure to warn.

“The Company will consider its legal options regarding the application of this ruling to other SVEC verdicts that are in conflict with it, as well as how this ruling could affect future trials.”

The SVEC cases represent most of PCB-related personal injury litigation against Monsanto. Erickson is the first personal injury case to go to trial due to alleged PCB exposure at a single school in Washington state.

The evidence in these cases have demonstrated that all measured PCB air concentrations at SVEC fell well below the regulatory health-protective limits and guidelines set by state and federal regulators, and there is no evidence any such exposure to PCBs can and did cause the alleged injuries.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Monsanto


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Monsanto

One A Day® Introduces New Women's Multi Gummy Formula with 1,000 mcg Biotin

WHIPPANY, N.J.--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand from Bayer, today announced a new formula for One A Day® Women's Multi Gummy, which now delivers 1,000 mcg of Biotin per serving (serving size is two gummies). The new formulation contains more biotin† with 2833% Daily Value (DV) than other leading multivitamin gummies including Olly Women’s Multi, Nature Made Women's Advanced Multivitamin Gummies, and Vitafusion Women's Multi (1000 mcg vs 150 mcg), while continu...

New Economist Enterprise Research Highlights Why Integrating Self-Care Into Health Systems Matters

LEVERKUSEN, Germany--(BUSINESS WIRE)--Self-care, when effectively integrated into health systems, can improve health outcomes, expand access to healthcare services and reduce pressure on overstretched health systems, according to new research by Economist Enterprise. The research, supported by Bayer and published in a report titled “Making self-care work: integrating self-care into health systems”, cites existing evidence estimating that self-care practices can deliver approximately US$ 179 bil...

Bayer and Henry Ford Health Announce Strategic Research Partnership to Expand Patient Access to Clinical Trials

DETROIT--(BUSINESS WIRE)--Bayer, a global life sciences company, and Henry Ford Health today announced a strategic partnership to expand clinical trial opportunities for patients. The work brings together Bayer’s global drug development expertise with Henry Ford Health’s comprehensive clinical research program and its deep connection to the communities it serves. “Clinical trials are often the first opportunity patients have to access cutting-edge treatments,” said Dr. David Lanfear, Chief Scie...
Back to Newsroom